Trial intelligence / Profile preview

PENG Block for Recovery After Primary Total Hip Arthroplasty

NCT04591353Phase 3

Key facts

Status: Completed
Start: Feb 2021
Primary completion: Sep 2022
Countries: 1
Sponsor: University of Alabama at Birmingham
Modality: Small Molecules

Drugs: bupivacaine
Conditions: postoperative pain

Overview

Phase 3, randomised, double-blind trial of bupivacaine in postoperative pain (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Quality of Recovery-15 Score at 24 hours. Started Feb 2021; status: completed.

Design

2 arms

Study design: RandomizedDouble-blind

PENG Block
Ultrasound-guided PENG block with 25cc 0.5% bupivacaine.
Control
Sham block with skin infiltration of lidocaine only.

Who it enrols

Adult patients undergoing primary total hip arthroplasty with ASA I-III. Excludes patients with chronic opioid use, coagulopathy, or contraindications to regional anesthesia.

Endpoints

Primary

Quality of Recovery-15 Score24 hours

Secondary

Quality of Recovery-15 Score48 hours
Average Pain Medicine Required After Surgery48 hours
Visual Analog Scale Pain Score48 hours
Ambulation Distance After Surgery48 hours
Total Patients Using Antiemetics After Surgery48 hours

Beyond the preview

Go deeper on NCT04591353.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04591353.